David A. Siegel Halozyme Therapeutics, Inc. Transaction History

Two Sigma Advisers, LP

$42.8 Billion
Q1 2025

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 293,729 shares of HALO stock, worth $17.1 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares

293,729

Previous 5,900 4878.46%

Holding current value

$17.1 Million

Previous $282,000 6546.1%

% of portfolio

0.04%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$47.74 - $65.16 $13.7 Million - $18.8 Million	287,829 Added 4878.46%	293,729 $18.7 Million
Q4 2024 Feb 14, 2025	BUY	$42.57 - $61.09 $251,163 - $360,431	5,900 New	5,900 $282,000
Q2 2023 Aug 14, 2023	SELL	$30.28 - $38.74 $9.03 Million - $11.6 Million	-298,300 Reduced 67.34%	144,700 $5.22 Million
Q1 2023 May 15, 2023	SELL	$32.86 - $55.7 $5.03 Million - $8.53 Million	-153,100 Reduced 25.68%	443,000 $16.9 Million
Q4 2022 Feb 14, 2023	BUY	$40.06 - $59.44 $10.6 Million - $15.7 Million	264,500 Added 79.76%	596,100 $33.9 Million
Q3 2022 Nov 14, 2022	SELL	$38.53 - $51.78 $2.26 Million - $3.03 Million	-58,600 Reduced 15.02%	331,600 $13.1 Million
Q3 2022 Nov 14, 2022	SELL	$38.53 - $51.78 $2.26 Million - $3.03 Million	-58,600 Reduced 15.02%	331,600 $13.1 Million
Q2 2022 Aug 15, 2022	BUY	$37.35 - $48.3 $14.4 Million - $18.6 Million	384,400 Added 6627.59%	390,200 $17.2 Million
Q1 2022 May 16, 2022	BUY	$31.97 - $41.06 $185,426 - $238,148	5,800 New	5,800 $231,000
Q4 2021 Feb 14, 2022	SELL	$31.82 - $40.75 $10.1 Million - $13 Million	-318,120 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$38.47 - $46.42 $8.37 Million - $10.1 Million	-217,700 Reduced 40.63%	318,120 $12.9 Million
Q2 2021 Aug 16, 2021	BUY	$38.84 - $51.31 $3.71 Million - $4.89 Million	95,400 Added 21.66%	535,820 $24.3 Million
Q1 2021 May 17, 2021	BUY	$39.51 - $51.45 $1.02 Million - $1.33 Million	25,800 Added 6.22%	440,420 $18.4 Million
Q4 2020 Feb 16, 2021	SELL	$25.81 - $43.62 $17.6 Million - $29.8 Million	-683,000 Reduced 62.23%	414,620 $17.7 Million
Q3 2020 Nov 16, 2020	SELL	$25.74 - $29.63 $9.45 Million - $10.9 Million	-367,300 Reduced 25.07%	1,097,620 $28.8 Million
Q2 2020 Aug 14, 2020	SELL	$16.25 - $26.81 $992,875 - $1.64 Million	-61,100 Reduced 4.0%	1,464,920 $39.3 Million
Q1 2020 May 15, 2020	BUY	$13.9 - $21.83 $7.5 Million - $11.8 Million	539,700 Added 54.72%	1,526,020 $27.5 Million
Q4 2019 Feb 14, 2020	BUY	$14.93 - $19.53 $9.5 Million - $12.4 Million	636,500 Added 181.95%	986,320 $17.5 Million
Q3 2019 Nov 14, 2019	BUY	$15.2 - $17.69 $259,920 - $302,499	17,100 Added 5.14%	349,820 $5.43 Million
Q2 2019 Aug 14, 2019	BUY	$14.75 - $17.26 $619,500 - $724,920	42,000 Added 14.45%	332,720 $5.72 Million
Q1 2019 May 15, 2019	SELL	$13.94 - $17.58 $2.29 Million - $2.89 Million	-164,300 Reduced 36.11%	290,720 $4.68 Million
Q4 2018 Feb 14, 2019	SELL	$13.33 - $18.66 $3.75 Million - $5.25 Million	-281,100 Reduced 38.19%	455,020 $6.66 Million
Q3 2018 Nov 14, 2018	SELL	$16.68 - $18.41 $3.44 Million - $3.8 Million	-206,400 Reduced 21.9%	736,120 $13.4 Million
Q2 2018 Aug 14, 2018	SELL	$16.87 - $20.3 $2.55 Million - $3.07 Million	-151,000 Reduced 13.81%	942,520 $15.9 Million
Q1 2018 May 15, 2018	BUY	$17.06 - $21.2 $6.7 Million - $8.33 Million	392,800 Added 56.06%	1,093,520 $21.4 Million
Q4 2017 Feb 14, 2018	BUY	$16.75 - $20.8 $9.6 Million - $11.9 Million	573,100 Added 449.07%	700,720 $14.2 Million
Q3 2017 Nov 14, 2017	BUY	$11.76 - $17.4 $1.5 Million - $2.22 Million	127,620	127,620 $2.22 Million

Others Institutions Holding HALO

# of Institutions

586

Shares Held

123M

Call Options Held

320K

Put Options Held

113K

View Full List

About HALOZYME THERAPEUTICS, INC.

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $8.11B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

More about HALO

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account